SCHEMBL274080

SCHEMBL274080

CCOC(=O)C1CN(C(=O)c2ccc3c(c2)OCO3)CCc2c1[nH]c1ccccc21

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.55
HPGD P15428 4/20 0.55
POLB P06746 1/20 0.55
PDE5A O76074 6/20 0.47
ADRA2A P08913 1/20 0.46
ADRA1A P35348 1/20 0.46
ELANE P08246 1/20 0.46
MAPT P10636 2/20 0.45
GAA P10253 1/20 0.45
HTT P42858 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
NPC1 O15118 1/20 0.44
TP53 P04637 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
TSHR P16473 1/20 0.44
HSD11B1 P28845 1/20 0.43
CHRM4 P08173 1/20 0.42
DRD2 P14416 1/20 0.42
HTR7 P34969 1/20 0.42
MEN1 O00255 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL273558 0.86 ABCG2 (0.52) ALDH1A1ADRA2AADRA1AMAPTGAA
SCHEMBL275317 0.84 MAPT (0.51) ALDH1A1ADRA2AADRA1AMAPTGAA
SCHEMBL273496 0.84 NR1H4 (0.56) ALDH1A1POLBADRA2AADRA1AMAPT
SCHEMBL275525 0.84 ALDH1A1 (0.55) ALDH1A1POLBADRA2AADRA1AMAPT
SCHEMBL274292 0.84 ABCG2 (0.58) ALDH1A1ADRA2AADRA1AMAPTGAA
SCHEMBL10290925 0.84 HPGD (0.52) HPGDPOLBADRA2AADRA1AMAPT
SCHEMBL275578 0.83 CDK4 (0.56) ALDH1A1ADRA2AADRA1AGAATP53
SCHEMBL275183 0.83 TRPV1 (0.47) ALDH1A1ADRA2AADRA1AMAPTGAA
SCHEMBL273349 0.82 ALDH1A1 (0.46) ALDH1A1POLBADRA2AADRA1AMAPT
SCHEMBL275616 0.81 SMN1; SMN2 (0.54) ALDH1A1HPGDPOLBADRA2AADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8524704-B2 Azepinoindole derivatives as pharmaceutical agents EXELIXIS, INC. (US) 2013-09-03 US disclosed
US-8133992-B2 Azepinoindole and pyridoindole derivatives as pharmaceutical agents EXELIXIS, INC. (US) 2012-03-13 US disclosed
EP-1532153-B1 AZEPINOINDOLE AND PYRIDOINDOLE DERIVATIVES AS PHARMACEUTICAL AGENTS X CEPTOR THERAPEUTICS INC (US) 2012-02-29 EP disclosed
US-20100173824-A1 Azepinoindole Derivatives As Pharmaceutical Agents EXELIXIS, INC. (US) 2010-07-08 US disclosed
US-20090326218-A1 Azepinoindole and Pyridoindole Derivatives as Pharmaceutical Agents EXELIXIS, INC. (US) 2009-12-31 US disclosed
US-7595311-B2 Modulating active of receptors; therapy prevention of disease such aas symthrome X, antidiabetic agents, insulin resistance, hypoglycemic agents EXELIXIS, INC. (US) 2009-09-29 US disclosed
US-7485634-B2 Azepinoindole and pyridoindole derivatives as pharmaceutical agents EXELIXIS, INC. (US) 2009-02-03 US disclosed
EP-1692136-A2 AZEPINOINDOLE DERIVATIVES AS PHARMACEUTICAL AGENTS X-Ceptor Therapeutics, Inc. (US) 2006-08-23 EP disclosed
WO-2005056554-A2 AZEPINOINDOLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS, INC. (US) 2005-06-23 WO disclosed
US-20050054634-A1 Modulating active of receptors; therapy prevention of disease such aas symthrome X, antidiabetic agents, insulin resistance, hypoglycemic agents AKARNA THERAPEUTICS, LTD. (GB) 2005-03-10 US disclosed
US-20040023947-A1 Azepinoindole and pyridoindole derivatives as pharmaceutical agents X-CEPTOR THERAPEUTICS INC. 2004-02-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040023947-A1 Azepinoindole and pyridoindole derivatives as pharmaceutical agents HTR5A, MTNR1A, PTGDR ALDH1A1 1722/4885HPGD 368/4885POLB 4706/4885
US-20100173824-A1 Azepinoindole Derivatives As Pharmaceutical Agents HTR2A, HTR5A, HTR2C ALDH1A1 1321/4885HPGD 550/4885POLB 4837/4885
US-20090326218-A1 Azepinoindole and Pyridoindole Derivatives as Pharmaceutical Agents HTR5A, MTNR1A, PTGDR ALDH1A1 1722/4885HPGD 368/4885POLB 4706/4885
US-20050054634-A1 Modulating active of receptors; therapy prevention of disease such aas symthrome X, antidiabetic agents, insulin resistance, hypoglycemic agents GPR119, IRS1, INSR ALDH1A1 3963/4885HPGD 3272/4885POLB 4761/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.